^
Association details:
| Biomarker: | PTEN mutation |
|---|---|
| Cancer: | Endometrial Cancer |
| Drug: | A66 (PI3K inhibitor) + AZD6482 (PI3Kβ inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PI3K pathway dependencies in endometrioid endometrial cancer cell lines
Excerpt:
PTEN-mutant EEC cell lines were resistant to the p110β inhibitors GSK2636771 and AZD6482, and only in combination with the p110α selective inhibitor A66, a decrease in cell viability was observed....hibition of p110β alone may not be sufficient to sensitize PTEN-mutant EEC cells and combination with other targeted agents may be required.
DOI:
10.1158/1078-0432.CCR-12-3815
